Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Niraparib Combined With Bevacizumab as Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-line Platinum-based Chemotherapy With Bevacizumab

NCT03326193 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT03326193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03326193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Niraparib Combined With Bevacizumab as Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-line Platinum-based Chemotherapy With Bevacizumab
Lead sponsor
Tesaro, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 12, 2017
Completion date
July 12, 2024
Enrollment
105 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms